Jon Napitupulu

Mesoblast has reshaped its board as it pivots from development to commercial execution following its first FDA approval and...

Zealand Pharma has set a 2030 agenda to become a next‑generation metabolic health leader, targeting five product launches, more...

Nasus Pharma has moved its intranasal epinephrine program, NS002, into a Health Canada–authorized Phase 2 study, has dosed the...

Intelligent Bio Solutions has struck a strategic manufacturing partnership with Syrma Johari Medtech to scale production of its intelligent...

Arvinas has secured FDA acceptance of the NDA for vepdegestrant, its oral PROTAC estrogen receptor degrader for ESR1‑mutated ER+/HER2‑...

Moonlake Immunotherapeutics reported third-quarter 2025 results, with $380.5 million in cash and committed debt, extending the runway into the...

EyePoint Pharmaceuticals has fully enrolled its two Phase 3 wet AMD trials, LUGANO and LUCIA, with more than 900...

Centessa Pharmaceuticals reported positive initial Phase 2a results for ORX750, its oral OX2R agonist, across narcolepsy type 1, narcolepsy...

Upstream Bio reported positive phase 2 results for verekitug in chronic rhinosinusitis with nasal polyps and outlined a near-term...

Foghorn Therapeutics reported steady progress across its chromatin-targeting pipeline, keeping its SMARCA2 inhibitor FHD-909 on track in a Phase...